Incyte Announces Proposed Public Offering of 4,945,000 Shares of Common Stock
The Company intends to use the net proceeds of this offering for general corporate purposes, including working capital, research and development activities, capital expenditures and potential strategic transactions.
BofA Merrill Lynch is acting as the sole underwriter of this offering.
The shares will be issued pursuant to an effective shelf registration statement. Before you invest, you should read the prospectus included in that registration statement and the documents incorporated by reference in that registration statement as well as the prospectus supplement related to the offering. You may obtain these documents free of charge by visiting EDGAR on the
This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy the Company’s common stock, nor shall there be any sale of the common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective shelf registration statement.
About
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements with respect to the proposed public offering of common stock, expectations with respect to granting the underwriter an option to purchase additional shares and the intended use of net proceeds from the offering, are all forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including those related to completion of the public offering on the anticipated terms or at all, market conditions, satisfaction of the conditions to closing of the proposed offering, risks relating to our dependence upon our revenues from JAKAFI, cash requirements arising from the development of new products by us and our current and potential collaborators, the risk of significant delays or costs in obtaining regulatory approvals, risks relating to our collaborators’ ability to develop and commercialize drug candidates, and cash requirements arising from our business development activities, the fact that
View source version on businesswire.com: http://www.businesswire.com/news/home/20170907006713/en/
Source:
Incyte Corporation
David W. Gryska, +1-302-498-6700
dgryska@incyte.com